CN107208133A - 用于治疗抑郁症的Val66Met (SNPrs6265)基因型特异性给药方案和方法 - Google Patents

用于治疗抑郁症的Val66Met (SNPrs6265)基因型特异性给药方案和方法 Download PDF

Info

Publication number
CN107208133A
CN107208133A CN201580061885.9A CN201580061885A CN107208133A CN 107208133 A CN107208133 A CN 107208133A CN 201580061885 A CN201580061885 A CN 201580061885A CN 107208133 A CN107208133 A CN 107208133A
Authority
CN
China
Prior art keywords
val
met
patient
depression
weeks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580061885.9A
Other languages
English (en)
Chinese (zh)
Inventor
L.I.卡尔斯
G.萨瓦多累
J.辛格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54200096&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN107208133(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of CN107208133A publication Critical patent/CN107208133A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Otolaryngology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN201580061885.9A 2014-09-15 2015-09-14 用于治疗抑郁症的Val66Met (SNPrs6265)基因型特异性给药方案和方法 Pending CN107208133A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462050439P 2014-09-15 2014-09-15
US62/050439 2014-09-15
PCT/US2015/049961 WO2016044150A1 (en) 2014-09-15 2015-09-14 VAL66MET (SNP rs6265) GENOTYPE SPECIFIC DOSING REGIMENS AND METHODS FOR THE TREATMENT OF DEPRESSION

Publications (1)

Publication Number Publication Date
CN107208133A true CN107208133A (zh) 2017-09-26

Family

ID=54200096

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580061885.9A Pending CN107208133A (zh) 2014-09-15 2015-09-14 用于治疗抑郁症的Val66Met (SNPrs6265)基因型特异性给药方案和方法

Country Status (11)

Country Link
US (6) US20160074340A1 (enExample)
EP (2) EP3725307A1 (enExample)
JP (2) JP2017528483A (enExample)
KR (1) KR20170054470A (enExample)
CN (1) CN107208133A (enExample)
AU (1) AU2015318123A1 (enExample)
CA (1) CA2961208A1 (enExample)
IL (2) IL251068A0 (enExample)
MA (1) MA40620A (enExample)
MX (1) MX2017003366A (enExample)
WO (1) WO2016044150A1 (enExample)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112188889A (zh) * 2018-06-27 2021-01-05 克雷西奥生物科技有限公司 治疗重度抑郁症的方法
CN112423789A (zh) * 2017-12-22 2021-02-26 詹森药业有限公司 用于治疗抑郁症的艾司氯胺酮
CN114007600A (zh) * 2019-04-09 2022-02-01 维斯塔津治疗公司 与神经系统病症的治疗响应有关的遗传变异
CN114126595A (zh) * 2019-03-05 2022-03-01 杨森制药公司 用于治疗抑郁症的艾司氯胺酮
CN115418398A (zh) * 2022-08-30 2022-12-02 广州医科大学附属脑科医院 一组用于预测氯胺酮治疗难治性抑郁症的疗效的标志物及其应用
US11957645B2 (en) 2018-10-05 2024-04-16 Clexio Biosciences Ltd. Method of treating major depressive disorder
US12478592B2 (en) 2019-12-30 2025-11-25 Clexio Biosciences Ltd. Dosage regime with esketamine for treating neuropsychiatric or neurological conditions

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014152196A1 (en) 2013-03-15 2014-09-25 Janssen Pharmaceutica Nv Pharmaceutical composition of s-ketamine hydrochloride
AU2015318123A1 (en) 2014-09-15 2017-03-30 Janssen Pharmaceutica Nv Val66Met (SNP rs6265) genotype specific dosing regimens and methods for the treatment of depression
US20160338977A1 (en) * 2015-05-20 2016-11-24 Janssen Pharmaceutica Nv Methods and kits for treating depression
US20190078161A1 (en) * 2016-03-18 2019-03-14 Tekada Pharmaceutical Company Limited Method for identifying clinical trial responders from a placebo group in major depression
AU2017351437B2 (en) * 2016-10-27 2022-01-27 National University Corporation Chiba University Application of (S)-norketamine and salt thereof as pharmaceutical
US20200009081A1 (en) 2017-09-13 2020-01-09 Janssen Pharmaceutica N.V. Delivery Of Esketamine For The Treatment Of Depression
PT3505157T (pt) 2017-12-29 2022-02-18 Celon Pharma Sa Composição de cetamina em pó seco para administração pulmonar em depressão resistente ao tratamento
WO2020075134A1 (en) 2018-10-11 2020-04-16 Clexio Biosciences Ltd. Esketamine for use in treating major depressive disorder
CA3133012A1 (en) * 2019-08-05 2021-02-11 The Ketamine Research Foundation Ketamine for the treatment of postpartum symptoms and disorders
EP4021432A4 (en) * 2019-08-28 2023-08-16 Janssen Pharmaceuticals, Inc. ESKETAMIN FOR THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER, INCLUDING SUICIDALITY
KR102312387B1 (ko) * 2019-11-15 2021-10-13 이화여자대학교 산학협력단 인지 증강을 위한 개인 맞춤형 경두개 직류 자극 프로토콜 생성 방법 및 장치
IL293506A (en) 2019-12-30 2022-08-01 Clexio Biosciences Ltd Dosage regime with esketamine for treating major depressive disorder
TW202139981A (zh) 2020-01-22 2021-11-01 美商西羅斯醫療公司 降低nmda拮抗劑之副作用
US20220175701A1 (en) * 2020-12-08 2022-06-09 Therapeutic Solutions International, Inc. Treatment of major depressive disorder and suicidal ideations through stimulation of hippocampal neurogenesis utilizing plant-based approaches
CN116942648A (zh) * 2022-04-26 2023-10-27 宜昌人福药业有限责任公司 艾司氯胺酮液体制剂及其用途
EP4642445A2 (en) * 2022-12-28 2025-11-05 Perception Neuroscience, Inc. Methods of administering r-ketamine

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140093592A1 (en) * 2012-03-12 2014-04-03 Janssen Pharmaceutica Nv Esketamine for the treatment of treatment-refractory or treatment-resistant depression

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH535201A (de) 1969-12-19 1973-03-31 Bristol Myers Co Verfahren zur Spaltung von racemischen 2-(o-Chlorphenyl)-2-methylaminocyclohexanon in die optisch-aktiven Isomeren
JPS632932A (ja) 1986-06-23 1988-01-07 Teijin Ltd 経鼻投与用粉末状組成物
USD308100S (en) 1987-08-28 1990-05-22 Schering Corporation Nasal spray pump
US5002935A (en) 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US4994467A (en) 1989-05-31 1991-02-19 Zimmerman Andrew W Treating autism and other developmental disorders in children with NMDA receptor antagonists
DE4312016A1 (de) 1993-04-13 1994-10-20 Goedecke Ag Stabile Ketamin-Lösungen
US5543434A (en) 1994-02-25 1996-08-06 Weg; Stuart L. Nasal administration of ketamine to manage pain
EP0814790B1 (en) 1995-02-24 2003-07-16 Stuart L. Weg Administration of ketamine for detoxification
WO1997007750A1 (en) 1995-08-30 1997-03-06 Weg Stuart L Administration of ketamine to manage pain and to reduce drug dependency
USD401323S (en) 1996-01-23 1998-11-17 Ing. Erich Pfeiffer Gmbh Medication dispensing apparatus
DE19619665C2 (de) 1996-05-15 2001-03-08 Goedecke Ag Racemattrennung von Ketamin
DE19723133A1 (de) 1997-06-03 1998-12-10 Caideil M P Teoranta Tourmakea Austragvorrichtung für Medien
AU135762S (en) 1998-01-09 1998-11-19 Astrazeneca Ab Sprayer
USD433123S (en) 1998-07-09 2000-10-31 Zeneca Limited Nasal spray
AU758679B2 (en) 1998-07-24 2003-03-27 Seo Hong Yoo Preparation of aqueous clear solution dosage forms with bile acids
US6176242B1 (en) 1999-04-30 2001-01-23 Medtronic Inc Method of treating manic depression by brain infusion
US6017961A (en) 1999-07-08 2000-01-25 Flores; John Anthony Ketamine and n-butyl-p-aminobezoate in PLO
EP1103256A1 (de) 1999-11-26 2001-05-30 Claudius Dr. med. Böck Verwendung von Ketamin zur Behandlung von neuroendokriner Immundysfunktion und algogenem Psychosyndrom
WO2002024116A1 (en) 2000-09-20 2002-03-28 Shahinian, Lee, Jr. Self-preserved nasal, inhalable, and topical ophthalmic preparations and medications
US6881731B1 (en) 2000-10-23 2005-04-19 Shanbrom Technologies, Llc Enhancers for microbiological disinfection
USD471973S1 (en) 2001-08-08 2003-03-18 N.V. Organon Applicator for a nasal delivery device
CA2529857A1 (en) 2002-07-30 2004-02-05 Peter Migaly Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions
US7273889B2 (en) 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
JP2006510618A (ja) 2002-11-18 2006-03-30 ヤウポン セラピューティクス，インコーポレーテッド ノルケタミンおよびケタミン／ノルケタミンプロドラッグの鎮痛的使用
US7687080B2 (en) 2002-11-25 2010-03-30 Taraxos Inc. Treatment of neuropathy
US20040214215A1 (en) 2003-03-07 2004-10-28 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
US8082173B2 (en) 2003-05-22 2011-12-20 Cecil Kost Drug sample fulfillment architecture
US20040265364A1 (en) 2003-06-25 2004-12-30 Binnur Ozturk Neuropathy cream
US20050095277A1 (en) 2003-06-25 2005-05-05 Binnur Ozturk Neuropathy cream
USD544957S1 (en) 2005-03-23 2007-06-19 Rexam Dispensing Systems Nasal spray dispenser
US20060223788A1 (en) 2005-03-29 2006-10-05 Cathcart Clifton H Analgesic composition for topical use
CA111438S (fr) 2005-05-23 2006-12-22 Rexam Dispensing Sys Pulvérisateur nasal
EP1885414B1 (en) 2005-06-01 2012-11-21 SHL Group AB Device for delivering medicament
US20060276550A1 (en) 2005-06-03 2006-12-07 Dileep Bhagwat Topical compositions of ketamine and butamben and methods of their use
CN101466364A (zh) 2006-03-22 2009-06-24 纽约大学西奈山医学院 鼻内施用氯胺酮治疗抑郁症
WO2007123945A2 (en) 2006-04-21 2007-11-01 Aradigm Corporation Mechanical single dose intrapulmonary drug delivery devices
AU2007253684A1 (en) 2006-05-22 2007-11-29 Vanda Pharmaceuticals, Inc. Treatment for depressive disorders
DE102007009888A1 (de) 2007-02-28 2008-09-04 Hermann, Holger Lars, Dr. Verwendung von S-(+)-Ketamin zur Behandlung von Depressionen
US20100095957A1 (en) 2007-03-02 2010-04-22 Corbco, Inc. Manually operated monodose nasal sprayer device
WO2008151179A2 (en) 2007-06-04 2008-12-11 Auspex Pharmaceuticals, Inc. Substituted phenethylamines
WO2009131794A1 (en) 2008-03-27 2009-10-29 University Of Kentucky Research Foundation Opioid-ketamine and norketamine codrug combinations for pain management
USD610678S1 (en) 2009-03-31 2010-02-23 Daikyo Seiko, Ltd. Syringe plunger and proximal end of a syringe barrel for a pre-filled nasal drip device
USD610253S1 (en) 2009-03-31 2010-02-16 Daikyo Seiko, Ltd. Pre-filled nasal drip device
US20120225949A1 (en) 2009-08-14 2012-09-06 Demitri Papalos Compositions and methods for treating bipolar disorder
US20110038807A1 (en) 2009-08-14 2011-02-17 Demitri Papolos Compositions and methods for treating bipolar disorder
EP2582366B1 (en) 2010-06-15 2015-10-28 Grünenthal GmbH Pharmaceutical combination for the treatment of pain
USD699342S1 (en) 2011-03-09 2014-02-11 Suzuken Company Limited Injector
WO2013003669A2 (en) 2011-06-30 2013-01-03 University Of South Florida Compositions, methods of use, and methods of treatment
USD697201S1 (en) 2011-07-01 2014-01-07 R5 Pharmaceuticals Limited Buccal delivery device adaptor
US20130056557A1 (en) 2011-09-02 2013-03-07 Maggie Blair Felder Non-pressurized flavored liquid oxygen breath spray device
EP2766339B1 (en) 2011-10-14 2021-06-09 The United States Of America, as represented by the Secretary, Department of Health & Human Services The use of (2r, 6r)-hydroxynorketamine and other stereoisomeric hydroxylated metabolites of (r,s)- ketamine in the treatment of depression and neuropathic pain
BR112014011491A2 (pt) 2011-11-14 2017-05-09 Nestec Sa ensaios e métodos para seleção de um regime de tratamento para um indivíduo com depressão
US20130209585A1 (en) 2012-02-13 2013-08-15 Stanley Kim Topical NMDA Antagonist Formulations for the Treatment of Peripheral Neuropathy
AU2016203771A1 (en) 2012-03-13 2016-06-23 Janssen Pharmaceutica Nv Esketamine for the treatment of treatment-refractory or treatment-resistant depression
JP2015512418A (ja) 2012-03-30 2015-04-27 ザ ジェネラル ホスピタル コーポレイション うつ病の治療におけるスコポラミンおよびケタミンを含む組成物
US20140079740A1 (en) 2012-08-02 2014-03-20 ClinPharm Support GmbH Oral transmucosal adminstration forms of s-ketamine
MX2015002378A (es) 2012-08-23 2015-09-25 Stuart L Weg Composicion ansiolitica, formulacion y metodo de uso.
FR2994844B1 (fr) 2012-08-31 2015-01-02 Assist Publ Hopitaux De Paris Formulation gelifiante a base de ketamine
NZ619257A (en) 2012-10-08 2015-07-31 Auckland Uniservices Ltd Ketamine derivatives
ES2484068B1 (es) 2013-02-08 2015-04-16 Ana MÍNGUEZ MARTÍ Una composición farmacéutica que contiene ketamina y amitriptilina
US20140263457A1 (en) 2013-03-15 2014-09-18 Launce R. Barber Child-resistant closure systems for containers
US20140263456A1 (en) 2013-03-15 2014-09-18 Launce R. Barber Child-resistant closure systems for containers
NZ713300A (en) 2013-04-12 2020-05-29 Icahn School Med Mount Sinai Method for treating post-traumatic stress disorder
EP3960162A1 (en) 2013-08-26 2022-03-02 Amorsa Therapeutics, Inc. Single-layer oral dose of neuro-attenuating ketamine
ES2897453T3 (es) 2013-09-13 2022-03-01 Univ Chiba Nat Univ Corp Aplicación de R-ketamina y sal de la misma como productos farmacéuticos
US9569220B2 (en) 2013-10-06 2017-02-14 Synopsys, Inc. Processor branch cache with secondary branches
CN103705909A (zh) 2013-12-16 2014-04-09 陈镜伊 一种无痛人流用药
WO2015101693A1 (es) 2013-12-31 2015-07-09 Servicio Andaluz De Salud Composiciones y preparaciones combinadas para el tratamiento de las algias orofaríngeas
EP3094312B1 (en) 2014-01-14 2019-03-13 Children's Hospital Medical Center Compositions comprising ketamine for treating an autism spectrum disorder
ES2829279T3 (es) 2014-04-17 2021-05-31 Develco Pharma Schweiz Ag Forma de dosificación oral de ketamina
FR3023188B1 (fr) 2014-07-04 2016-08-19 Aptar France Sas Dispositif de distribution de produit fluide.
WO2016025581A1 (en) 2014-08-13 2016-02-18 Janssen Pharmaceutica Nv Method for the treatment of depression
AU2015318123A1 (en) 2014-09-15 2017-03-30 Janssen Pharmaceutica Nv Val66Met (SNP rs6265) genotype specific dosing regimens and methods for the treatment of depression
EP3240422A1 (en) 2014-12-31 2017-11-08 Icahn School of Medicine at Mount Sinai Method of maintaining the anti-depressant effect of ketamine with lithium
CN104798728A (zh) 2015-05-08 2015-07-29 南京中医药大学 产后抑郁动物模型的建立方法及其应用
US20160332962A1 (en) 2015-05-13 2016-11-17 Janssen Pharmaceutica Nv (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
US20160338977A1 (en) 2015-05-20 2016-11-24 Janssen Pharmaceutica Nv Methods and kits for treating depression
US11191734B2 (en) 2015-06-27 2021-12-07 Shenox Pharmaceuticals, Llc Ketamine transdermal delivery system
US20180296478A1 (en) 2016-02-12 2018-10-18 Synergistic Therapeutics, Llc Sublingual antidepressant and antianxiety tablet
US20180042936A1 (en) 2016-03-18 2018-02-15 Genomind, Inc. Maintenance therapy using tianeptine
CA3086478A1 (en) 2017-12-22 2019-06-27 Janssen Pharmaceuticals, Inc. Esketamine for the treatment of depression

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140093592A1 (en) * 2012-03-12 2014-04-03 Janssen Pharmaceutica Nv Esketamine for the treatment of treatment-refractory or treatment-resistant depression

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
GONZALO LAJE等: "Brain-Derived Neurotrophic Factor Val66Met Polymorphism and Antidepressant Efficacy of Ketamine in Depressed Patients", 《BIOL PSYCHIATRY》 *
LUCIANA RIBEIRO等: "The brain-derived neurotrophic factor rs6265 (Val66Met) polymorphism and depression in Mexican-Americans", 《NEUROREPORT》 *
ZEZHI LI 等: "The role of BDNF, NTRK2 gene and their interaction in development of treatment-resistant depression: Data from multicenter, prospective,longitudinal clinic practice", 《JOURNAL OF PSYCHIATRIC RESEARCH》 *
匿名: "NCTO2133001 on 20140623: ClinicalTrials. gov Archive", 《CLINICALTRIALS》 *
沈一峰: "脑源性神经营养因子与抗抑郁药疗效的关系", 《中国博士学位论文全文数据库》 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112423789A (zh) * 2017-12-22 2021-02-26 詹森药业有限公司 用于治疗抑郁症的艾司氯胺酮
US11707440B2 (en) 2017-12-22 2023-07-25 Janssen Pharmaceuticals, Inc. Esketamine for the treatment of depression
CN112188889A (zh) * 2018-06-27 2021-01-05 克雷西奥生物科技有限公司 治疗重度抑郁症的方法
US12036189B2 (en) 2018-06-27 2024-07-16 Clexio Biosciences Ltd. Method of treating major depressive disorder
US11957645B2 (en) 2018-10-05 2024-04-16 Clexio Biosciences Ltd. Method of treating major depressive disorder
CN114126595A (zh) * 2019-03-05 2022-03-01 杨森制药公司 用于治疗抑郁症的艾司氯胺酮
CN114007600A (zh) * 2019-04-09 2022-02-01 维斯塔津治疗公司 与神经系统病症的治疗响应有关的遗传变异
US12478592B2 (en) 2019-12-30 2025-11-25 Clexio Biosciences Ltd. Dosage regime with esketamine for treating neuropsychiatric or neurological conditions
CN115418398A (zh) * 2022-08-30 2022-12-02 广州医科大学附属脑科医院 一组用于预测氯胺酮治疗难治性抑郁症的疗效的标志物及其应用
CN115418398B (zh) * 2022-08-30 2025-02-18 广州医科大学附属脑科医院 一组用于预测氯胺酮治疗难治性抑郁症的疗效的标志物及其应用

Also Published As

Publication number Publication date
US20200246279A1 (en) 2020-08-06
MA40620A (fr) 2016-03-24
JP2017528483A (ja) 2017-09-28
EP3725307A1 (en) 2020-10-21
US20210106545A1 (en) 2021-04-15
US11311500B2 (en) 2022-04-26
US20250255835A1 (en) 2025-08-14
CA2961208A1 (en) 2016-03-24
IL279119A (en) 2021-01-31
US20230089113A1 (en) 2023-03-23
US20160074340A1 (en) 2016-03-17
JP2021054829A (ja) 2021-04-08
EP3193853A1 (en) 2017-07-26
WO2016044150A1 (en) 2016-03-24
US20210308076A1 (en) 2021-10-07
AU2015318123A1 (en) 2017-03-30
MX2017003366A (es) 2018-02-01
KR20170054470A (ko) 2017-05-17
IL251068A0 (en) 2017-04-30
US10869844B2 (en) 2020-12-22
US11173134B2 (en) 2021-11-16

Similar Documents

Publication Publication Date Title
US20230089113A1 (en) Methods For The Treatment Of Depression
JP6545788B2 (ja) うつ病の治療方法
AU2023237026A1 (en) Methods and kits for treating depression
EP1691811B1 (en) Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
JP6286696B2 (ja) Ｄｒｄ２又はａｎｋｋ１のｓｎｐ遺伝子型に基づく抗精神病治療
Richelson Treatment of acute depression
CN119174751A (zh) 用于治疗焦虑相关病症的组合物和方法
Farmer et al. Pharmacological intervention for disruptive behaviors in intellectual and developmental disabilities: the glass is half full
JP7773909B2 (ja) 筋痛性脳脊髄炎／慢性疲労症候群治療剤
CN118401239A (zh) 用于治疗抑郁症，包括难治性抑郁症的2-氟脱氯氯胺酮
HK1095279B (en) Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20170926